NCT04963153 2026-04-13
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
22 trialsNCT05239624 2026-04-13
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07421700 2026-04-07
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Recruiting
NCT07484022 2026-04-07
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Recruiting
NCT07287995 2026-04-01
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT05923190 2026-03-19
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT06862219 2026-03-06
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Astellas Pharma Inc
Phase 4 Recruiting
NCT07221942 2026-02-19
IMPROEV
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06483334 2026-02-18
MK-3475-04C
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05868265 2026-02-17
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07183319 2026-02-02
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Phase 2 Recruiting
NCT04878029 2026-01-23
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Emory University
Phase 1 Recruiting
NCT03869190 2026-01-22
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1/2 Completed
NCT05014139 2025-11-20
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Inc
Phase 1 Terminated
NCT06356155 2025-07-29
NEPTUNE
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05524545 2025-07-25
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
ALX Oncology Inc.
Phase 1 Completed
NCT06493552 2025-04-03
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Phase 2/3 Recruiting
NCT03070990 2024-10-18
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Astellas Pharma Inc
Phase 1 Completed
NCT03219333 2024-08-27
EV-201
Astellas Pharma Inc
Phase 2 Completed
NCT03606174 2023-08-24
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Mirati Therapeutics Inc.
Phase 2 Terminated